Alexandria Venture Investments
Facts
- HQ
- Los Angeles
- Sectors
- Venture Capital, Biotech Investment
Judge Orders Guardant Health to Pay $245M to TwinStrand and University of Washington, Plus 6% Royalties Through March 2033
A federal judge ordered Guardant Health to pay more than $245 million to TwinStrand Biosciences and the University of Washington for willful infringement of Duplex Sequencing patents and imposed a 6% royalty on covered sales through March 2033. The judgment includes jury damages, supplemental damages, accrued royalties and interest, and recognizes UW-developed technology that greatly increases DNA sequencing accuracy.
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Vedana Therapeutics Raises $46M Series A Led by Westlake BioPartners and Canaan Partners for Migraine Therapy Development
Vedana Therapeutics, a Seattle-based biotech company focused on migraine prevention therapies, raised $46 million in a Series A funding round. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Biopharma.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Lila Biologics, Nobel Laureate’s Startup, Partners with Eli Lilly to Develop AI-Based Tumor Therapies
Lila Biologics, a startup from Nobel Laureate David Baker's University of Washington lab, is collaborating with Eli Lilly to develop AI-powered tumor-targeted therapies, aiming to deliver a candidate protein for clinical trials within six months. The startup utilizes AI and machine learning platforms to create therapeutic proteins for targeted radiotherapy and long-acting injectable drugs.
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
Archon Biosciences Raises $20M to Develop AI-Optimized Antibody Cages for Disease Treatment
Archon Biosciences has emerged from stealth with $20 million in seed funding led by Madrona Ventures to develop Antibody Cages, computationally designed protein structures optimized with AI for treating cancer and other diseases. The technology builds on protein design research linked to a recent Nobel Prize awarded to University of Washington biochemist David Baker.
AltPep Raises $52.9M to Advance Early Detection and Treatments for Alzheimer’s and Parkinson’s Diseases
AltPep, a University of Washington spinout developing tests and treatments for Alzheimer’s and Parkinson’s, raised $52.9 million in Series B funding to advance clinical trials and regulatory approval for its early detection blood test. The company targets toxic oligomers linked to Alzheimer’s and a related protein in Parkinson’s, aiming to enable early screening and preventive treatment.
Mozart Therapeutics Raises $25M to Advance Autoimmune Disease Drug MTX-101 with FDA IND Planned for Early 2024
Seattle biotech Mozart Therapeutics secured $25 million to advance MTX-101, its drug candidate for autoimmune gastrointestinal diseases, aiming for FDA IND submission by early 2024. The company, led by CEO Katie Fanning and supported by notable investors, has raised a total of $80 million since its 2020 launch.
Seattle Startup Cajal Neuroscience Raises $96M to Develop New Alzheimer's and Parkinson's Treatments
Seattle-based startup Cajal Neuroscience, founded in 2020, has raised $96 million to develop treatments for neurodegenerative diseases like Alzheimer's and Parkinson's by exploring diverse drug targets beyond amyloid-beta. The company aims to understand genetic variants' roles in disease mechanisms to identify key molecules involved in neurodegeneration.
UW spinout AltPep raises $44.4M as its Alzheimer’s blood test earns FDA breakthrough designation
University of Washington spinout AltPep raised $44.4 million and is developing experimental blood tests to detect Alzheimer’s and Parkinson’s diseases early, plus treatments; its Alzheimer’s test received FDA breakthrough device designation. The three-year-old Seattle startup has 25 employees, raised $23.1M in a 2021 Series A, is hiring, and is pursuing partnerships and clinical-ready development.
Alexandria Executive Chairman Joel Marcus Says Pandemic Is Shifting Biotech Toward Hubs Like Seattle as Investment Surges
Alexandria Real Estate Equities chairman Joel Marcus says the pandemic is accelerating biotech investment and changing industry geography, reinforcing hubs like Seattle where his company has extensive lab real estate, tenants, and venture investments.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
TwinStrand Biosciences, led by Jesse Salk, raises $50M Series B from Section 32 to scale ultra-accurate gene-sequencing
TwinStrand Biosciences, co-founded and led by Jesse Salk, raised $50 million in a Series B led by Section 32 to expand its high-accuracy gene-sequencing technology for detecting rare mutations with applications in cancer detection, therapy monitoring, and safety testing.
Ensoma launches in Boston with $70M Series A to commercialize Engenious gene‑editing adenoviral vectors developed by Fred Hutch and UW researchers
Boston-based biotech spinout Ensoma launched, announcing a $70 million Series A to commercialize Engenious adenoviral vectors developed by Drs. Hans-Peter Kiem (Fred Hutch) and André Lieber (UW) that aim to deliver single‑injection gene therapies without stem cell harvest or chemotherapy.
AltPep, UW spinout led by Valerie Daggett, raises $23.1M Series A to develop early-detection and therapeutics for Alzheimer’s
Seattle biotech AltPep, spun out of the University of Washington in 2019 and led by founder/CEO Valerie Daggett, raised $23.1 million in a Series A to develop detection tools and preclinical therapies for Alzheimer’s and other amyloid protein diseases. The company’s technology, based on UW-licensed research into alpha-sheet protein structures, will support early detection efforts and expansion into a new 7,500 sq ft Seattle lab.
